Novo Nordisk Scores Asian Regulatory Win as Options Market Flags Underlying Caution
Published on 07/09/2026 at 16:02 | Redaktion boerse-global.de
Novo Nordisk's weight-loss franchise received a significant endorsement from Singapore's drug regulator, which has expanded the official label for Wegovy based on data from the Phase 3b STEP-UP trial. The study demonstrated that a third of participants lost at least 25% of their body weight over 72 weeks, with an average reduction of 21%. Crucially, the trial showed that up to 84% of the weight lost came from fat rather than muscle, and patients reported a sharp decline in impulsive eating urges. The company’s regional medical leadership described the findings as a paradigm shift, arguing that treatment success should no longer be measured solely by absolute weight loss but by how the weight is shed.
Yet despite the positive clinical headlines, sentiment in the derivatives market tells a different story. The put-to-call ratio stands at 1.38, more than double the typical reading of 0.62 for the stock, indicating that options traders are heavily hedging against downside. That caution is understandable given the price action: the shares recently traded at €42.87, representing a 17% gain over the past month but still 28% below the peak set last July. With a price-to-earnings ratio of just 11.5, the equity looks cheap on a fundamental basis, but the options market suggests investors are not ready to bet on a sustained recovery.
The Danish pharmaceutical giant is working to support its stock through an aggressive buyback program. Management is authorized to repurchase up to 11.2 billion Danish kroner of its own B-shares through February 2027. So far, the company has spent roughly 6.2 billion kroner to acquire 23 million shares, bringing its treasury stock to 40.1 million shares, equivalent to about 1% of total share capital. The buyback removes supply from the market and provides a price floor, though its impact is being tested by operational headwinds.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analyst sentiment remains mixed, with HSBC lifting its price target to 300 Danish kroner from 280 while retaining a hold rating. Among 24 analysts covering the stock, only seven recommend a buy, while the majority sit on the fence. The upgrade reflects some confidence in Novo Nordisk’s long-term prospects, but the lack of bullish consensus underscores the competitive threats the company faces.
Those threats are becoming increasingly tangible, particularly in Asia. In South Korea, Novo Nordisk is restructuring its local operations, merging its obesity and diabetes units to speed up decision-making against Eli Lilly. The US rival has made deep inroads: during the first quarter, Lilly sold roughly 323 billion won worth of weight-loss injections in Korea, while Novo Nordisk’s Wegovy generated just 104 billion won. The picture is even starker in the United States, where Lilly’s Zepbound has overtaken Wegovy as the market leader, accounting for nearly 60% of weekly prescriptions and building a lead of more than 100,000 scripts per week.
Technically, the stock has found support near its 50-day moving average of €39.37, and as long as that level holds, the short-term uptrend of recent weeks remains intact. The buyback program adds another layer of downside protection, but the real test for Novo Nordisk is whether it can slow Lilly’s momentum in key markets. Success in the Korean reorganization will be critical; if the restructuring fails to deliver faster responses, the company risks accelerated market-share erosion in other regions. For now, the options market is pricing in that risk even as the clinical data provides a fresh narrative for Wegovy’s efficacy.
Ad
Novo Nordisk Stock: New Analysis - 9 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
